Once-Daily Cefazolin and Probenecid for Skin and Soft Tissue Infections

Abstract

Spanish

French

OBJECTIVE

To review the pharmacokinetic and clinical evidence for the use of once-daily cefazolin and probenecid in the treatment of skin and soft tissue infections (SSTI).

DATA SOURCES

MEDLINE (1966–July 2003), EMBASE (1980–July 2003), and PubMed (1966–July 2003) databases for English language, human reports were searched. Search terms included cefazolin, probenecid, cellulitis, and soft tissue infections.

STUDY SELECTION AND DATA EXTRACTION

Studies that described pharmacokinetic and clinical outcomes that evaluated the use of cefazolin in conjunction with probenecid for SSTI were included. All studies were evaluated independently by both authors. For pharmacokinetic studies, the effect of probenecid on the pharmacokinetics of cefazolin was evaluated. For clinical trials, efficacy and safety endpoints were evaluated. For efficacy endpoints, definition of cure was used as defined by each trial.

DATA SYNTHESIS

In all 3 pharmacokinetic studies identified, the addition of probenecid to cefazolin therapy prolonged the half-life and increased serum concentrations of cefazolin. This process allowed serum concentrations to be above the minimal inhibitory concentrations (MIC) for the most likely skin pathogens (Staphylococcus aureus, β-hemolytic streptococci) at the end of the dosing interval. In the first of 2 clinical trials, 7 (7%) of 96 patients receiving intravenous ceftriaxone 2 g and oral probenecid 1 g daily were reported to fail therapy compared with 8 (8%) of 98 patients receiving intravenous cefazolin 2 g and oral probenecid 1 g daily. In the second clinical trial, clinical success was reported in 51 (86%) of 59 patients receiving the same doses of cefazolin and probenecid as above compared with 55 (96%) of 57 patients receiving intravenous ceftriaxone 1 g and oral placebo daily.

CONCLUSIONS

Limited pharmacokinetic and clinical data suggest that intravenous cefazolin 2 g and oral probenecid 1 g daily is an effective regimen in the treatment of SSTI.

Keywords

cefazolin cellulitis probenecid skin and soft tissue infections

Get full access to this article

View all access options for this article.

References

1. Hook

Hooton

Horton

Coyle

Ramsey

Turck

Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986;146:295–7.

2. Goldgeier

MH.

The microbial evaluation of acute cellulitis. Cutis 1983;31:649–56.

3. Sachs

MK.

The optimum use of needle aspiration in the bacteriologic diagnosis of cellulitis in adults. Arch Intern Med 1990;150:1907–12.

4. Ginsberg

MB.

Cellulitis: analysis of 101 cases and review of the literature. South Med J 1981;74:530–3.

5. Bradsher

Snow

RM.

Ceftriaxone treatment of skin and soft tissue infections in a once daily regimen. Am J Med 1984;77:63–7.

6. Gordin

Wofsy

Mills

Once-daily ceftriaxone for skin and soft tissue infections. Antimicrob Agents Chemother 1985;27:648–9.

7. Scully

Neu

HC.

Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection. Am J Med 1984;77:112–7.

8. Goldstein

Topiel

Ehrlich

Simon

A comparative study of ceftriaxone vs cefazolin in the treatment of cellulitis. Curr Ther Res 1984;36:653–7.

9. Slutkin

Marzouk

Dall

Mills

Comparision of cefonicid and cefazolin for treatment of soft tissue infections. Rev Infect Dis 1984;6(suppl 4):S853–6.

10.

10. Parish

Witkowski

JA.

Ceforanide compared with cefazolin in skin and soft tissue infections. Cutis 1984;33:313–9.

11.

11. Chirurgi

Edelstein

Oster

Karp

Cassano

Aiken

Randomized comparison trial of teicoplanin IV, teicoplanin IM and cefazolin for skin and soft tissue infections caused by gram-positive bacteria. South Med J 1994;87:875–80.

12.

12. Brown

Chamberlain

Goulding

Clarke

Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. J Emerg Med 1996;14:547–51.

13.

13. Grayson

McDonald

Gibson

Athan

Munckhof

Paull

Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. Clin Infect Dis 2002;34:1440–8.

14.

14. Stevens

DL.

Teicoplanin for skin and soft tissue infections: an open study and randomized, comparative trial versus cefazolin. J Infect Chemother 1999;5:40–5.

15.

15. Dong

Kelly

Oland

Holroyd

Rowe

BH.

ED management of cellulitis: a review of five urban centers. Am J Emerg Med 2001;19:535–40.

16.

16. Cephalosporins. In: McEvoy

, ed. American Society of Health-System Pharmacists drug information. 45th ed. Bethesda, MD: American Society of Health-System Pharmacists American Hospital Formulary Service, 2003:125–223.

17.

17. Uricosuric agents. In: McEvoy

, ed. American Society of Health-System Pharmacists drug information. 45th ed. Bethesda, MD: American Society of Health-System Pharmacists American Hospital Formulary Service, 2003:2557–62.

18.

18. Cunningham

Israili

Dayton

PG.

Clinical pharmacokinetics of probenecid. Clin Pharmacokinet 1981;6:135–51.

19.

19. Tjandramaga

Cucinell

Israili

Perel

Dayton

Observations on the disposition of probenecid in patients receiving allopurinol. Pharmacology 1972;8:259–72.

20.

20. Brown

GR.

Cephalosporin-probenecid drug interactions. Clin Pharmacokinet 1993;24:289–300.

21.

21. Zed

Harder

Harrison

Purssell

RA.

Efficacy of once daily cefazolin/probenecid for the outpatient management of skin and soft tissue infections (abstract). Can J Emerg Med 2001;3:139–40.

22.

22. Kirby

WMM

Regamey

Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis 1973;128(suppl):S341–5.

23.

23. Karney

Turck

Holmes

KK.

Cefazolin in the treatment of gonorrhea. J Infect Dis 1973;128(suppl):S399–403.

24.

24. Duncan

WC.

Treatment of gonorrhea with cefazolin plus probenecid. J Infect Dis 1974;130:398–401.

25.

25. Rein

Westervelt

Sande

MA.

Pharmacodynamics of cefazolin in the presence of normal and impaired renal function. Antimicrob Agents Chemother 1973;4:366–71.

26.

26. Brown

Zemcov

SJV

Clarke

AM.

Effect of probenecid on cefazolin serum concentrations. J Antimicrob Chemother 1993;31:1009–11.

27.

27. Spina

Dillon

Jr. Effect of chronic probenecid therapy on cefazolin serum concentrations. Ann Pharmacother 2003;37:621–4. DOI 10.1345/aph.1C347.

28.

28. Burgess

DS.

Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999;115(3 suppl):19S–23S.

29.

29. Gunderson

Ross

Ibrahim

Rotschafer

JC.

What do we really know about antibiotic pharmacodynamics?

Pharmacotherapy 2001;21 (11 pt 2):302S–18S.

30.

30. Rodvold

KA.

Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside. Pharmacotherapy 2001;21(11 pt 2):319S–30S.

31.

31. Craig

WA.

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Mcrobiol Infect Dis 1995;22:89–96.

32.

32. Craig

WA.

Antimicrobial resistance issues of the future. Diagn Mcrobiol Infect Dis 1996;25:213–7.

33.

33. Craig

Andes

Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255–9.

34.

34. Andes

Craig

WA.

Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am 1998;12:849–60.

35.

35. Karchmer

AW.

Cephalosporins. In: Mandell

Bennett

Dolin

, eds. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone, 2000:274–91.

36.

36. Stoeckel

Trueb

Dubach

McNamara

PJ.

Effect of probenecid on the elimination and protein binding of ceftriaxone. Eur J Clin Pharmacol 1988;34:151–6.

37.

37. Performance standards for antimicrobial susceptibility testing; twelfth informational supplement. NCCLS document M100-S12. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.